Correlation between pentraxin-3 and endothelial dysfunction in obstructive sleep apnea syndrome

Area of Science:

• Cardiology
• Sleep Medicine
• Inflammation Research

Background:

• Obstructive sleep apnea syndrome (OSAS) is a known cardiovascular disease risk factor.
• Endothelial dysfunction and pentraxin-3 are early markers of cardiovascular disease development.
• The study investigates the link between OSAS severity and these markers.

Purpose of the Study:

• To evaluate the relationship between OSAS severity and endothelial dysfunction.
• To assess the association between OSAS severity and inflammatory markers, specifically pentraxin-3 and hs-CRP.
• To understand the role of pentraxin-3 and endothelial dysfunction in OSAS.

Main Methods:

• Cross-sectional study design.
• Patients grouped by apnea-hypopnea index (AHI): mild OSAS (5–14.9), moderate-severe OSAS (≥15), and controls (<5).
• Endothelial function assessed via flow-mediated dilatation (FMD); serum pentraxin-3 and hs-CRP levels measured.

Main Results:

• Significant increases in pentraxin-3 and hs-CRP levels with increasing OSAS severity.
• Significant decrease in FMD as OSAS severity increased.
• Negative correlation found between FMD and AHI, pentraxin-3, and hs-CRP.

Conclusions:

• OSAS patients exhibit elevated pentraxin-3 levels and endothelial dysfunction.
• Both pentraxin-3 and endothelial dysfunction are independently associated with OSAS severity (AHI).
• Findings suggest pentraxin-3 and endothelial dysfunction are key indicators in OSAS-related cardiovascular risk.